Prognostic impact of cortactin in patients with hypopharyngeal cancer and its role for tegafur-uracil maintenance after adjuvant chemoradiotherapy.
Cortactin
chemoradiotherapy
hypopharyngeal cancer
prognosis
survival
tegafur-uracil
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
08
2023
accepted:
06
11
2023
medline:
7
12
2023
pubmed:
7
12
2023
entrez:
7
12
2023
Statut:
epublish
Résumé
The prognosis of patients with hypopharyngeal cancer (HPC) remains poor. Our study aims to investigate the prognostic impact of cortactin in patients with HPC and its role for tegafur-uracil (UFUR) maintenance after adjuvant chemoradiotherapy (CRT). Patients who were diagnosed to have HPC and underwent laryngopharyngectomy followed by adjuvant CRT were enrolled into our study. Immunohistochemical staining was performed for cortactin evaluation. Kaplan-Meier curves were depicted for recurrence-free survival (RFS) and overall survival (OS). A total of 157 patients were enrolled into our study. After stratified by cortactin, 53 patients were cortactin (+) and 104 patients were cortactin (-). The median RFS was 86.7 months in cortactin (-) and 10.2 months in cortactin (+) (P < 0.001). The median OS was 93.4 months in cortactin (-) and 16.9 months in cortactin (+) (P < 0.001). Patients were further classified according to UFUR maintenance or not after adjuvant CRT. In cortactin (+) patients, the median RFS and OS were 13.6 months versus 7.0 months (P = 0.006) and 24.0 months versus 10.0 months (P < 0.001) in UFUR (+) and UFUR (-), respectively. In cortactin (-) patients, the median RFS and OS were 96.0 months versus 72.2 months (P = 0.262) and 98.5 months versus 105.0 months (P = 0.665) in UFUR (+) and UFUR (-), respectively. Cortactin has a significantly impact in HPC patients. UFUR maintenance provided survival benefits in patients with cortactin (+) after adjuvant CRT.
Types de publication
Journal Article
Langues
eng
Pagination
5504-5512Informations de copyright
AJCR Copyright © 2023.
Déclaration de conflit d'intérêts
None.
Références
Cancer Res. 2006 Dec 15;66(24):11690-9
pubmed: 17178864
Exp Cell Res. 2006 May 15;312(9):1658-70
pubmed: 16527272
Am J Otolaryngol. 2021 Nov-Dec;42(6):103156
pubmed: 34242883
Biochim Biophys Acta. 2007 Jun;1775(2):263-73
pubmed: 17292556
Biology (Basel). 2021 Feb 23;10(2):
pubmed: 33672266
Med Oncol. 2014 Sep;31(9):178
pubmed: 25131963
Laryngoscope. 2015 Mar;125(3):624-9
pubmed: 25220657
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncogene. 2017 Jun 1;36(22):3104-3118
pubmed: 28068324
Pathol Oncol Res. 2010 Dec;16(4):523-31
pubmed: 20069395
Clin Cancer Res. 2000 Aug;6(8):3177-82
pubmed: 10955801
J Mol Diagn. 2003 Feb;5(1):48-53
pubmed: 12552080
Auris Nasus Larynx. 2019 Apr;46(2):260-266
pubmed: 30107961
Biochim Biophys Acta. 2007 May;1773(5):642-52
pubmed: 16926057
J Gastrointest Surg. 2010 Aug;14(8):1248-57
pubmed: 20532661
J Cell Sci. 2012 Apr 1;125(Pt 7):1621-6
pubmed: 22566665
Cancer Res. 2001 Feb 1;61(3):1029-37
pubmed: 11221829
Mol Cell Biol. 2010 Nov;30(21):5057-70
pubmed: 20805359
Eur Arch Otorhinolaryngol. 2018 Jan;275(1):181-189
pubmed: 29080963
Clin Transl Oncol. 2016 Feb;18(2):220-7
pubmed: 26243395
Oncol Lett. 2017 Dec;14(6):6754-6762
pubmed: 29163699
Int J Oncol. 2015 Sep;47(3):1034-42
pubmed: 26151562
World J Gastroenterol. 2014 Mar 28;20(12):3287-300
pubmed: 24696610
Head Neck. 2019 Nov;41(11):3775-3782
pubmed: 31435974
Am J Pathol. 2020 May;190(5):958-967
pubmed: 32084363